Amylyx Q1 net loss $35.9M, cash $204.1M; avexitide Phase 3 underway

Amylyx Pharmaceuticals, Inc.

2025-Q1 EPS reported -$0.42

Q1 net loss $35.9M ($0.42/share), down from $118.8M ($1.75/share) YoY on lower R&D and SG&A costs.
Cash, equivalents, and marketable securities $204.1M; cash runway expected through end of 2026.
Phase 3 LUCIDITY trial of avexitide in PBH dosed first patient; enrollment complete 2025, topline data H1 2026.
Phase 1 LUMINA trial of AMX0114 (ASO for ALS) dosed first patient; early cohort data expected in 2025.
Closed $65.5M public offering of 19.7M shares in Jan 2025; Phase 2b ORION (PSP) data expected Q3 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.